TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Guoqiong LeiSushun LiuXin YangChao HePublished in: Canadian journal of gastroenterology & hepatology (2021)
In mutant P53 colon cancer cell HT29, TRIM29 greatly increased the sensitivity of HT29 to oxaliplatin and reverse oxaliplatin resistance. The underlying mechanism is TRIM29 may increase the sensitivity of HT29 to oxaliplatin by blocking the transcriptional function of mutant P53, which inhibits the transcription function of its downstream gene such as MDR1.